Chargement en cours...
Real World Experience with Tofacitinib in IBD at a Tertiary Center
BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...
Enregistré dans:
| Publié dans: | Dig Dis Sci |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/ https://ncbi.nlm.nih.gov/pubmed/30734234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|